Interestingly, MM-EVs treated with bortezomib or lenalidomide exhibit decreased ability to activate NF-κB and to induce VEGF, IL-6, and bFGF expression in endothelial cells, thus showing decreased angiogenic potential [43,51]. The gene discussed is IL6; the disease is Miyoshi myopathy.